The Treatment of High-Risk Smoldering Myeloma
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.
The current standard of care for these patients is to follow and check blood test, though there is no evidence to suggest this is the best practice, Landgren says.
In his presentation at the 17th International Congress on Hematologic Malignancies, Landgren gave an overview of the landscape regard other options in this disease type: ongoing studies, imaging, and molecular profiling studies.
Clinical Pearls
Landgren believes that there will soon be a change in the standard of care, though it is not time to start treating patients outside of clinical trials.
- The current standard of care for patients with high-risk smoldering myeloma is to follow and check blood tests
- Landgren predicts a change in the standard of care in the near future
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
